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Abstract 42 
 43 
Delayed controlled release is an innovative strategy to locally administer 44 
therapeutic compounds (e.g. chemotherapeutics, antibodies etc.). This would 45 
improve efficiency and reduce side effects compared to systemic administration. 46 
To enable the evaluation of the efficacy of controlled release strategies both in 47 
vitro and in vivo, we investigated the release of contrast agents (19F-FDG and 48 
BaSO4) to the intestinal tract from capsules coated with pH-sensitive polymers 49 
(Eudragit L-100) by using two complementary techniques, i.e. 19F magnetic 50 
resonance imaging (MRI) and computed tomography (CT). 51 
 52 
Using in vitro 19F-MRI, we were able to non-destructively and dynamically 53 
establish a time window of two hours during which the capsules are resistant to 54 
low pH.  With 19F-MRI, we could establish the exact time point when the capsules 55 
became water permeable, before physical degradation of the capsule. This was 56 
complemented by CT imaging that provided longitudinal information on physical 57 
degradation of the capsule at low pH that was only seen after 230 minutes. After 58 
oral administration to hamsters, 19F-MRI visualized the early event whereby the 59 
capsule becomes water permeable after 2 hours. Additionally, using CT, the 60 
integrity and location (stomach and small intestines) of the capsule after 61 
administration could be monitored. 62 
 63 
In conclusion, we propose combined 19F-MRI and CT to non-invasively visualize 64 
the different temporal and spatial events regarding the release of compounds, 65 
both in an in vitro setting as in the gastrointestinal tract of small animal models. 66 
This multimodal imaging approach will enable the in vitro and in vivo evaluation 67 
of further technical improvements to controlled release strategies.   68 
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Introduction 69 
 70 
Controlled release of therapeutic compounds at the disease location is a strategy 71 
that aims for a local effect and more precise targeting of pathological processes. 72 
It is anticipated that oral administration and delivery of therapeutic compounds 73 
directly inside the intestine (also called luminal delivery) can have considerable 74 
advantages over systemic administration. These include lower concentrations of 75 
drug needed, which reduces costs and lowers systemic side effects (1). One 76 
example where targeted delivery to the gastrointestinal tract could improve 77 
outcome is the controlled and localized release of antibodies targeting virulence 78 
factors against Clostridium difficile associated disease, which accounts for 71% of 79 
gastrointestinal nosocomial infections, but has currently a cure rate of only 70% 80 
with standard systemic administration of antibiotics (2-5). 81 
 82 
This situation and other clinical settings may benefit from an approach where 83 
therapeutic compounds are enclosed within a capsule for oral administration, 84 
designed to release its content only when it reaches its target location, in this 85 
case the small intestine. The pH in the human gastrointestinal tract increases 86 
progressively from the stomach (pH 2-3), the small intestine (pH 6.5-7) to the 87 
colon (pH 7-7.8) (6), with intra- and inter-individual differences. This makes it 88 
possible to coat a capsule with a polymer that is resistant to low pH and thus 89 
passes the stomach and dissolves at increased pH in a specific part of the 90 
gastrointestinal tract. Targeted drug release by capsules coated with pH-91 
sensitive materials has been described for a wide variety of cases (7). A rise in 92 
pH induces dissolution or swelling of the polymers, thereby leading to a 93 
disruption of the capsule coating, resulting in the release of its content (8).  94 
 95 
Delivery of a drug inside the gastrointestinal tract can be analyzed with a variety 96 
of techniques including enzyme-linked immunosorbent assay and mass 97 
spectrometry on luminal content (9,10). Nevertheless, these techniques have the 98 
disadvantage that animals need to be sacrificed for sample collection. Moreover, 99 
these approaches only provide snapshot data on the location and physical 100 
integrity of the capsule at the moment of sacrifice, and lack information on 101 
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compound release. The existing non-invasive option, i.e. measuring drug levels in 102 
fecal samples, lacks information on the exact site of release. To validate and 103 
optimize controlled release strategies and enable translational studies 104 
evaluating these novel therapeutic approaches, there is the need for a sensitive, 105 
non-invasive method to longitudinally evaluate capsule integrity, the anatomical 106 
location and the (early) release of compounds. 107 
 108 
Different medical imaging modalities have been applied frequently in both 109 
clinical and pre-clinical research providing new perspectives for biomedical 110 
research (11). Despite differences in resolution, sensitivity, penetration and 111 
safety, the main advantage of imaging techniques is that they provide non-112 
invasive, non-destructive and direct information both in vitro and in vivo. As such, 113 
gamma scintillation is frequently used as an imaging technique in clinical 114 
research for controlled release studies (12,13). It offers good sensitivity and a 115 
relatively simple procedure for acquiring images to follow capsule movement by 116 
means of a radioactive tracer that is included in the capsule just before 117 
administration. A potential concern with this technique is the need of gamma 118 
emitting radionuclides, which may hinder longitudinal monitoring due to their 119 
restricted half-lives and involve possible safety issues. Furthermore, the low 120 
resolution and the lack of anatomical background information make it difficult to 121 
interpret the images. Alternatively, endoscopy has also been applied for direct 122 
visualization of intraluminal drug delivery studies in humans (14). Although this 123 
technique could provide direct information regarding time and place of capsule 124 
rupture, dispersion characteristics and the surrounding physiological 125 
environment, the investigation with the large encapsulated camera is intrusive 126 
and offers only a limited field of view. 127 
 128 
In a preclinical research context, there is even more need for a sensitive, non-129 
invasive approach to evaluate controlled release in the 3D-context of the 130 
animal’s anatomy. MRI and CT are valuable imaging modalities, employed in a 131 
wide range of studies thanks to their ability to provide 3D anatomical images 132 
with excellent resolution and without the need for radioactive tracers (11). 133 
Especially MRI has been employed in pharmaceutical studies as it is devoid of 134 
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any ionizing radiation (15,16). Due to its relatively low sensitivity, conventional 135 
contrast agents such as superparamagnetic iron oxide and paramagnetic 136 
gadolinium/manganese are frequently used to enhance the contrast against the 137 
background (17-19). However, the contrast generated by those agents is not 138 
directly quantifiable and not always unambiguous due to similar intrinsic 139 
contrast changes, in particular in the abdomen. This can be overcome by the use 140 
of 19F-containing contrast agents. These have shown to be complementary to the 141 
acquisition of traditional proton-based, anatomical images (1H-MRI) (20). Due to 142 
the lack of MR-detectable 19F signal inside biological tissues, all signal from 19F-143 
MRI origins from the (dissolved) contrast agent, which makes the technique very 144 
specific and quantifiable (21). In this study, 2-fluoro-2-deoxy-D-glucose (19F-FDG) 145 
is used as contrast agent for 19F-MRI as it is only MR-detectable when dissolved 146 
in water and, as a glucose analog, is considered to be safe (22). On the other hand, 147 
barium sulphate (BaSO4), based on the high atom-number and hence high x-ray 148 
absorption of barium, is used as a CT contrast agent for gastrointestinal tract 149 
imaging to increase the contrast between the gastrointestinal contents compared 150 
to the surrounding soft tissues (23,24). Moreover, BaSO4 can be safely used for 151 
oral administration because of the absence of toxicity (25). 152 
 153 
By loading the pH-sensitive capsules with both contrast agents and by combining 154 
CT and 19F MRI, we hypothesized that the 19F-MRI FDG signal would provide 155 
information on early permeability of the capsule material to water and its 156 
location, while the BaSO4 contrast and the CT images can be used to monitor 157 
capsule integrity and the exact anatomical location of the site of release. 158 
 159 
In this study, we evaluated the ability of this dual imaging approach as a tool to 160 
evaluate the resistance of coated capsules at different pHs in vitro and in vivo 161 
after oral administration to hamsters. The objective is to combine different 162 
imaging modalities to non-destructively and longitudinally visualize and explore 163 
the kinetics of controlled release under different conditions.  164 
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Results and Discussion 165 
 166 
In vitro imaging 167 
In a first set of experiments, we conducted in vitro studies to investigate the 168 
resistance of coated capsules at different levels of acidity (pH = 1, 3, 5 and 7) 169 
with both MRI and CT (figure 1 and 2, respectively). For MR imaging, the 19F 170 
signal was overlaid with the anatomical 1H image. At the first time point, one 171 
hour after the capsule was added to the solutions, the capsules at pH 5 and 7 172 
showed quantifiable 19F-FDG signal (figure 1A). This indicates that the 173 
surrounding solution enters into the capsule and dissolves some of the otherwise 174 
not visible, encapsulated 19F-FDG, which was then picked up by 19F-MRI. This is 175 
in contrast to the capsules at low pH (pH 1 and 3), where the 19F-MRI signal 176 
could only be seen after one hour and a half (figure 1D), which indicates that the 177 
coating has more resistance at lower pH than at higher pH. In the timeframe of 2-178 
4 hours, for the capsules at all pHs, maximal signal intensity was reached, albeit 179 
at different time points (figure 1B and D). The time point at which the maximal 180 
signal intensity was reached, depended on the extra-capsular pH. The lower the 181 
pH, the longer the time needed to fully dissolve the 19F-FDG (figure 1D). In 182 
general, the 19F-MRI signal was first limited to the area of the actual capsule, 183 
indicating that although the 19F-FDG inside the capsule was dissolved, the 184 
exchange with the extra-capsular space was slow. After the 19F-FDG peak 185 
intensity reached a maximum, the signal gradually d creased (figure 1D). This 186 
process could be explained by the gradual diffusion of the 19F-FDG outside the 187 
capsule, which was confirmed by a rise in signal intensity observed in a MRI slice 188 
outside the capsule but inside the microcentrifuge tube (figure 1E). Later, this 189 
process is further accelerated by the degradation of the capsule. The signal 190 
intensity ratio between the intra- and extra-capsular spaces reached an 191 
equilibrium after 8-10 hours (depending on the pH). A macroscopic examination 192 
of the phantom after the MRI session confirmed that the capsules were degraded 193 
and their content dissolved. 194 
 195 
More information about the structure of the capsule with higher spatial and 196 
temporal resolution was acquired by performing CT of capsules containing 197 
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BaSO4 (figure 2). The time span of the longitudinal scans that were acquired 198 
from the same material as for the MRI experiments was limited to 8 hours. The 199 
results of the CT imaging clearly showed the degradation of the capsule after 230 200 
minutes in pH 5 and 7. The red arrowheads in figure 2 indicate the site of the 201 
capsule where degradation was first observed. This confirms the observation 202 
that the coated capsules are resistant to low pH. The physical degradation could 203 
be clearly visualized leading to the loss of contrast from the capsule material (see 204 
arrows in figure 2). The degradation of the capsule coincided with the 205 
accumulation of BaSO4 on the bottom of the microcentrifuge tube. Based on 206 
these results, CT imaging provides additional information about the later event 207 
of physical capsule degradation after the early increased permeability that was 208 
observed by MRI. The fact that there is no clear difference between the timing of 209 
degradation at pHs 5 and 7 does not conflict with the strategy to achieve a 210 
controlled release upon transit through the stomach, which normally has a lower 211 
pH. A complete degradation of all capsules at pH 1 was only observed after 400 212 
minutes. 213 
 214 
Based on the data acquired from the in vitro assessment of the low pH resistance 215 
of the coated capsules, we showed that MRI and CT result in complementary data 216 
regarding both permeability of the capsule to water and degradation of the 217 
capsule. Moreover, we demonstrated the resistance against low pH for up to 2 218 
hours by MRI and CT, which overcomes the normal transit time of the stomach 219 
(26). 220 
 221 
In vivo imaging 222 
In a next set of experiments, we longitudinally monitored capsules containing 223 
both 19F-FDG and BaSO4 using in vivo MRI and CT after oral administration to 224 
hamsters. In all animals, a clear 19F-MRI signal was observed in the stomach 2 225 
hours after administration (figure 3A-C). The extent of the detected 19F-MRI 226 
signal was within the range of the physical size of the capsule based on the 1H-227 
MR images. This indicates that fluid from the stomach entered into the capsule 228 
and dissolved the 19F-FDG. However, the capsule was not disintegrated. This is in 229 
line with the in vitro results. Figure 3D shows that after 5 hours, there was no 230 
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detectable 19F-MRI signal due to the degradation of the capsule leading to the 231 
release of 19F-FDG from the capsule and further dilution of the 19F-MRI signal 232 
below the detectability threshold. Non-localized in vivo 19F NMR spectra of the 233 
abdominal cavity show similar signal amplitudes at these two time points, which 234 
confirmed that the total amount of 19F -FDG inside the animal remains at a 235 
similar level but is no longer entirely localized in the capsule after 5 hours 236 
(figure 3E). The 19F NMR spectra in figure 3E were generated by using a non-237 
localized single pulse sequence instead of the localized PRESS sequence to cover 238 
the whole field of view. Quantification of the 19F-signal normalized to the signal 239 
at the 2 hour time point confirms almost constant signal intensity (100 % vs 97 240 
%, insert in figure 3E).  241 
 242 
CT of the same capsule and animal was also used for the localization of the 243 
capsule and the assessment of the integrity of the capsule (figure 4). The BaSO4-244 
containing capsule was clearly visible in the stomach right after administration, 245 
even from a 2D, non-reconstructed projection image (figure 4A). The early 246 
events of increased permeability of the capsule, as was seen by 19F-MRI, could 247 
not be visualized by CT. On the other hand, a clear degradation of the capsule and 248 
the release of the mainly non-dissolved BaSO4-content into the stomach were 249 
observed after 6 hours (figure 4B-D). CT using BaSO4 gives anatomical 250 
information with good sensitivity and high resolution both spatially and 251 
temporally. It provides positive contrast from the beginning until the 252 
degradation of the capsule and enables imaging of release of the solid capsule 253 
content into the gastrointestinal tract. The insolubility of barium salts has 254 
particularly the advantage that the contrast agent is trapped in the 255 
gastrointestinal tract resulting in reduced toxicity.  256 
 257 
The in vivo findings verify our in vitro results that the coated capsule could resist 258 
the low pH environment of the stomach without degradation for at least two 259 
hours. During this time, the location and integrity of the capsule can be 260 
monitored with CT, for both cases where the capsule remains trapped in the 261 
stomach for 6 hours (3 out of 4 hamsters tested), or passes the stomach and 262 
reached the small intestine (1 observation), 3 hours after administration (figure 263 
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5), consistent with previous studies in rats regarding capsule size and gastric 264 
retention (24,27). When 19F-FDG is dissolved, diffused out of the capsule and 265 
taken up by cells/ in the blood stream, it leads to the loss of a clearly localized 266 
19F-MRI signal (figure 5A). The feeding status of animals is a known factor that 267 
influences the transit of capsules (24). In our study, all animals were in a fed 268 
state. Another important aspect is the time during the day (activity vs. resting  269 
phase) when the capsule was administered. In this study, hamsters were dosed 270 
with the capsules during the light cycle. However, we did not observe any 271 
difference in transit time when the capsules were administered during the dark 272 
cycle (n=2, data not shown).  273 
 274 
The dual-modal imaging approach proposed in this study could in principle be 275 
applied to any other studies of controlled release from capsule material as both 276 
CT and MRI are readily available in modern clinical and pre-clinical 277 
environments for routine diagnosis and research purpose. Barium sulfate 278 
enhanced CT has already been used for gastrointestinal tract imaging to increase 279 
the contrast between the gastrointestinal contents compared to the surrounding 280 
soft tissues (24) due to the high atom-number and hence high x-ray absorption 281 
of barium. Furthermore, barium sulfate can also be safely used for oral 282 
administration because of the absence of toxicity (25). 283 
 284 
On the other hand, to the best of our knowledge, this is the first time that 19F-MRI 285 
was applied for controlled release studies from capsule material in an animal 286 
model. Thanks to its high specificity and quantitative feature, 19F-MRI used in 287 
this study provides detailed information to better understand the early events of 288 
capsule degradation, starting with an increase in permeability leading to an 289 
influx of liquids. Due to the relatively low sensitivity of MRI and the relatively 290 
low concentrations of 19F-FDG, 19F-MRI as applied in our study has only a 291 
temporal resolution in the order of 30 minutes and does not provide information 292 
on the capsule itself once the 19F-FDG has been released. Optimization of the 293 
magnetic resonance pulse sequence could be a key to reduce the scan time. This 294 
was shown to result in similar signal-to-noise ratio but reduced scan time, which 295 
should be further explored by analyzing the characteristics of 19FDG (20). 296 
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Recently, compressed sensing is also considered a reliable reconstruction 297 
technique to speed up the MRI scanning. According to Zhong et al., by under-298 
sampling the k-space factor of 8, compressed sensing could still retrieve the 299 
image with a similar signal-to-noise-ratio (28). Other methods including 300 
different coil set-ups and higher field strength could also be considered as 301 
potential ways to improve the sensitivity of the technique, reducing scan time 302 
and thus improving temporal resolution. The 19F-MRI technique could 303 
potentially be applied for clinical use as clinical trials have already been carried 304 
out by using perfluorocarbons (4). The safety of fluorodeoxyflucose at 305 
physiological concentrations has been demonstrated by its frequent use as a 306 
tracer for positr n emission tomography in the clinic (29). Higher FDG 307 
concentrations used for 19F MRI have not yet been assessed from a toxicological 308 
point of view. However, some pre-clinical studies did not indicate any adverse 309 
effects (22). 310 
 311 
Based on our proof-of-principle data, a future step will be to evaluate a pH-312 
controlled delivery in the gastrointestinal tract of antibodies against C. difficile by 313 
a pH-sensitive polymer coated capsule. Our dual-modality imaging approach 314 
enabled us to evaluate in vivo both the location and integrity of the capsule. As 315 
antibodies are generally well soluble, we would anticipate that they will 316 
distribute similar to the FDG used in our study. In order to test antibody release 317 
in the hamster model, parameters like different capsule sizes or capsule coating 318 
have to be further optimized for their ability to pass the stomach. By reducing 319 
the size of the capsule or modifying capsule coating to withstand low pH for 320 
longer, we expect the success rate to increase. 321 
  322 
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Conclusions 323 
We were able to show that combined application of 19F-MRI and CT provides 324 
information on the location, integrity and graduate release of material from oral 325 
administered capsules into the gastrointestinal tract of small animal models. 326 
This will form the basis for further studies on the delivery of therapeutic 327 
compounds, e.g. antibodies against Clostridium difficile infection.  328 
 329 
Both imaging modalities provide complementary information about the position 330 
and release of contrast agents (or drugs) inside the gastrointestinal tract. CT was 331 
shown to be useful for monitoring the localization of the capsule as well as the 332 
integrity of it. On the other hand, 19F-MRI enabled the visualization of the rise in 333 
permeability of the capsule. A 19F-MRI signal could only be detected when 19F-334 
FDG was dissolved and this happened when there was influx of water into the 335 
capsule. Furthermore, it should be noted that the degree of compound release is 336 
influenced by the solubility of the compound itself. For example, lyophilized 337 
antibodies can be stable and are well solubilized. As an intermediate step in the 338 
development of the oral administration of encapsulated antibodies, we envisage 339 
capsules to be filled with both, 19F-FDG and BaSO4 as well as the antibody. In that 340 
way the controlled release can be monitored non-invasively. 341 
 342 
Overall, we have proposed and demonstrated an imaging platform to monitor 343 
the mechanism of controlled release in vitro and in vivo. This multimodal 344 
platform could overcome the limitations in terms of sensitivity, resolution, 345 
specificity and quantitation of one individual method. We believe that this 346 
imaging approach could also be applied to other models where controlled 347 
release mechanisms need to be understood and evaluated.   348 
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Experimental 349 
Capsules and contrast agents 350 
Gelatin size 9 capsules (8.4 mm in length, 2.7 mm external diameter and 25 μl 351 
maximal volume, Torpac, Fairfield, USA) were filled with FDG and/or BaSO4 352 
(average amounts were 3.63 mg (equal to 20 μmol) and 14.49 mg (equal to 62 353 
μmol), respectively). Afterwards, the capsules were dip-coated with a solution of 354 
12.5% Eudragit L100 (Evonik Industries, Essen, Germany) in isopropanol. 355 
Triethylcitrate (10% w/w) was added as plasticizer. 356 
 357 
Hamster model 358 
All animal experiments were executed in accordance with national and European 359 
regulations and approved by the Animal Ethics Committee of the KU Leuven 360 
(approval numbers P009/2010 and P083/2011). Four male Syrian Golden 361 
hamsters (120-150 g, Janvier Laboratories) were given capsules via oral gavage 362 
using a dosing syringe (Torpac, Fairfield, USA). All animals were dosed and 363 
imaged during the light cyclus while being in a fed ad libitum. Additional 364 
experiments were performed whereby two animals were dosed and imaged 365 
during the dark cyclus but this did not impact the results discussed here (data 366 
not shown). 367 
 368 
Magnetic Resonance Imaging  369 
MRI was carried out on a 9.4 Tesla Bruker Biospec small animal MR scanner 370 
(Bruker Biospin, Ettlingen, Germany; horizontal bore, 20cm) equipped with 371 
actively shielded gradients (600 mT m-1) and running under the operating 372 
system ParaVision 5.1. For radiofrequency transmission and reception, a home-373 
built, inductively coupled, saddle shaped surface coil, tunable from 376 MHz for 374 
19F to 400 MHz for 1H was used for all experiments.  375 
 376 
For in vitro MRI, a phantom was prepared by filling 2% agarose in a plastic 377 
container containing 4 microcentrifuge tubes (Eppendorf, Hamburg, Germany). 378 
Each tube contained 400 µl PBS with different pH (pH = 1, 3, 5 and 7) adjusted by 379 
adding HCl (1M).  In each tube, one intact capsule loaded with 19F-FDG was 380 
added. A positioning and anatomic 1H-MRI scan was performed using a 2D turbo 381 
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spin echo sequence (RARE sequence, 8 echoes/excitation, 7.6 s/15.9 ms 382 
repetition time/effective echo time, 6.4 cm*6.4 cm field of view, 256*256 matrix, 383 
100 consecutive, coronal, 0.25 mm slice thickness, number of average is 2, 6 min 384 
scanning time). The settings for non-localized 19F-NMR spectroscopy were: 100 385 
ms repetition time, 1000 numbers of average, flip angle of 20° and total scan 386 
time of 100 s. 19F-MRI 2D images were obtained using the same sequence as for 387 
1H-MRI imaging with some parameters modified (1.142 s repetition time, 64*64 388 
matrix, 15 consecutive 1 mm thick slices in coronal orientation, 250 number of 389 
average, 28:30 min scan time). Repeated in vitro images were acquired over a 390 
period of 15 hours, until the capsules were considered to be totally disintegrated.  391 
 392 
For in vivo MRI, hamsters were scanned under inhalation anesthesia (1-2%  393 
isoflurane mixed with carrier gas oxygen).  A monitoring and gating model (type 394 
1030) from SA Instruments Inc. (Stony Brook, NY, USA) was used to regulate the 395 
physiological parameters and respiratory gating in real time.  The body 396 
temperature and respiration rate of animals were monitored using a rectal probe 397 
and a pressure sensitive pad placed underneath the thorax, respectively. Both 398 
body temperature and respiration rate were maintained at reasonable 399 
physiological range of approximately 37°C and 30-50 breaths/min, respectively. 400 
Both anatomical images (1H-MRI) and 19F-MR images were acquired using RARE 401 
sequences with modified parameters: 15.9 ms effective echo time; 6 s (1H)/1 s 402 
(19F) repetition time, 8 echoes/excitation; 6 cm * 8 cm field of view; 300*400 403 
(1H)/50*50 (19F) matrix; 50 (1H)/10 (19F) consecutive, coronal slices of 0.5 mm 404 
(for 1H) and 2.5 mm (for 19F) thickness; number of averages was 2 for 1H and 405 
500 for 19F; scan time was 7:24 min for 1H and 33:20 min for 19F. Multiple 19F MR 406 
images were obtained using the same scan protocol. The total scan time was 407 
maximum 2.5 hours. The 19F NMR spectra were analyzed using the Jmri software, 408 
version 4.0 (30).  409 
 410 
Computed Tomography 411 
CT images were acquired on a dedicated small animal microCT scanner (SkyScan 412 
1076, Bruker microCT, Kontich, Belgium), reconstructed and visualized using 413 
software provided by the manufacturer (NRecon, DataViewer, CTvox). 414 
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In vitro microCT phantom scans were acquired using the following scan 415 
parameters: 100 kVp X-ray source voltage combined with a 1.0 mm aluminum 416 
filter, 100 µA source current, 220 ms exposure time per projection, resulting in a 417 
total scan time of less than 7 minutes. 418 
 419 
For the acquisition of in vivo CT scans, hamsters were anesthetized with 1.5 – 1% 420 
isoflurane in 100 % oxygen.  Scan parameters were: 50 kVp X-ray source voltage 421 
combined with a 0.5 mm aluminum filter, 180 µA source current, 450 ms 422 
exposure time per projection, acquiring 2 projections (for averaging) per 423 
position with 0.7° increments over a total angle of 180° and a field-of-view 424 
covering the stomach and bowels, resulting in a scanning time of 12 minutes. 425 
This yielded a reconstructed 3D datasets with 35 µm³ isotropic voxel size.   426 
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Figure legends 427 
Figure 1: In vitro 19F-MRI monitoring. Coated capsules containing 19F-FDG in 428 
microcentrifuge tubes containing solutions of different pH were monitored for 429 
15 hours by 19F-MRI. The time to reach the maximum signal intensity depended 430 
on the pH in which the capsule was incubated. The 19F NMR signal was first 431 
detectable in the capsules incubated at the highest pH. After three hours, a signal 432 
was observed for all capsules incubated within the pH-range 1 to 7. A-C: 433 
representative 1H-MRI slices (gray scale) are overlaid with the corresponding 19F 434 
signal (red-hot scale) after 1 (A), 3 (B) and 15 hours (C) in the solution. The same 435 
19F-MRI signal intensity threshold was set manually for all images. (D-E): 436 
Quantitative 19F-MRI signal inside (D) and outside (E) the capsule of a 437 
representative slice based on the 1H-MRI image. Time resolution is 30 mins for 438 
the different pHs. The signal intensities are normalized to the maximum signal 439 
intensity (=100%) of the slice inside the capsule. Signal intensities were 440 
retrieved from locations corresponding to the intra-capsular space (D) or from a 441 
slice outside the capsule (E). 442 
 443 
Figure 2: In vitro CT monitoring. Coated capsules containing BaSO4 in 444 
microcentrifuge tubes containing solutions at different pH (indicated in the 445 
figure by 1, 3, 5 and 7) were monitored for 8 hours by CT. Upper row: 446 
longitudinal 2D projection images; bottom row: corresponding 3D volume-447 
rendered reconstructed images. Capsule disintegration only occured after 230 448 
min at pH 5 and 7, whereas at pH 1 the capsule only disintegrated after 400 min. 449 
Note: all capsules have the same size, the apparent different size between 450 
different capsules is due to the 3D rendering viewing angle. The red arrows 451 
indicate the site in the capsule where the first clear indication of degradation is 452 
observed. 453 
 454 
Figure 3: In vivo MRI monitoring of the 19F-MR signal in the digestive track 455 
of hamsters. Coated capsules containing 19F-FDG and BaSO4 were administered 456 
to hamsters and subsequently visualized by 19F-MRI. A: representative 1H-MR 457 
image slice visualizing the stomach; B: corresponding 19F MR image (grey scale) 458 
two hours after oral administration of the capsule (grey scale) and C: composite 459 
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of A and B (with the 19F MR image red-hot scaled with a manually set threshold), 460 
illustrating that after 2 hours, a 19F signal clearly localizes in the stomach. D: 461 
corresponding 19F-MR image five hours after capsule administration (grey scale) 462 
that shows the absence of detectable localized signal, indicating the complete 463 
disintegration of the capsule and uptake of 19F-FDG. E: Non-localized 19F-NMR 464 
spectra acquired by a pulse-acquisition sequence from the abdominal region at 465 
the same 2 (lower spectrum) and 5 hour (upper spectrum) time points. The 466 
insert shows the quantification of the MR spectrum normalized to the signal at 467 
the two hour time point. These data illustrate that the total signal intensity of 468 
19F-FDG inside the body has not changed. However, it is more dispersed, 469 
resulting in the absence of a localized 19F-MRI signal after 5 hours. The two 19F 470 
MR spectra were purposely shifted to enable better visualization and 471 
discrimination between the two spectra.  472 
 473 
Figure 4: CT of the capsule localized in the stomach. Coated capsules 474 
containing 19F-FDG and BaSO4 were administered to hamsters and subsequently 475 
visualized by CT. The stomach is filled with contrast agent six hours after 476 
administering the capsule. A: 2D projection image of a capsule (red arrow) right 477 
after administration, showing the intact capsule at the level of  the stomach. B-D 478 
Reconstructed image 6 hours after administration of sagittal view (B), transverse 479 
view (C) and coronal view (D), illustrating the disintegration of the capsule 480 
inside the stomach. The red arrows indicate the location of the capsule inside the 481 
stomach, encircled in red in (C). The stomach content is hyperintense due to 482 
BaSO4 released from the capsule. 483 
 484 
Figure 5: CT and MRI of the capsule localized in the small intestine. Coated 485 
capsule containing 19F-FDG and BaSO4 was localized (red arrow) in the small 486 
intestine 3 hours after administration. A: 19F-NMR spectrum shows the presence 487 
of 19F-FDG inside the body (arrow indicates the 19F peak). B-D: Reconstructed 488 
CT image of sagittal (B), transverse (C) and coronal view (D), demonstrating the 489 
presence of capsule remains and released BaSO4 in the small bowel of the 490 
hamster.  491 
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